Mirati Therapeutics (NASDAQ:MRTX) Price Target Cut to $45.00 by Analysts at B. Riley

Mirati Therapeutics (NASDAQ:MRTX – Free Report) had its price objective cut by B. Riley from $51.00 to $45.00 in a research note released on Monday, Marketbeat.com reports. They currently have a neutral rating on the biotechnology company’s stock. B. Riley also issued estimates for Mirati Therapeutics’ FY2024 earnings at ($9.27) EPS and FY2025 earnings at […]

Related Keywords

United States ,Jamie Christensen ,Laurie Stelzer ,Stifel Nicolaus ,Securities Exchange Commission ,Quent Capital ,Century Group ,Mirati Therapeutics Inc ,Barclays ,Advisor Group Holdings Inc ,Mirati Therapeutics Company Profile ,Mirati Therapeutics ,Free Report ,Mirati Therapeutic ,Get Free Report ,Exchange Commission ,Group Holdings ,Financial Advisors ,Neo Ivy Capital Management ,Mirati Therapeutics Daily ,Nasdaq Mrtx ,Mrtx ,Medical ,Lower Price Target ,B Riley ,